Sphingolipids in cell signaling: Their function as receptor ligands, second messengers, and raft constituents

Current Immunology Reviews

Volumn 2, Issue 1, 2006, Pages 101-118

  Baumruker, Thomas ^a   Billich, Andreas ^a  

^a Novartis Institutes for BioMedical Research Vienna   (Austria)

Author keywords

Cell signaling; G protein coupled receptors; Mediators; Rafts; Second messenger molecules; Sphingolipids

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM; CELL SURFACE RECEPTOR; CERAMIDE DERIVATIVE; CISPLATIN; DACTINOMYCIN; FINGOLIMOD; LIGAND; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSPORT; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; HUMAN; IMMUNOMODULATION; LIPID ANALYSIS; LIPID RAFT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SECOND MESSENGER; T LYMPHOCYTE ACTIVATION;

EID: 33745900222     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339506775471929     Document Type: Review

References (214)

1. Thudichum JLW. A treatise on the chemical constitutents of the brain (a facsimile edition of the original). Edited by Bailliere. London: 1962.
2. Ginzburg L, Kacher Y, Futerman AH. The pathogenesis of glycosphingolipid storage disorders. Semin Cell Dev Biol 2004; 15: 417-431.
3. Suzuki K. Twenty five years of the "psychosine hypothesis": a personal perspective of its history and present status. Neurochem Res 1998; 23: 251-259.
4. Carter HE, Johnson P, Weber EJ. Glycolipids. Annu Rev Biochem 1965; 34: 109-142.
5. Hannun YA, Loomis CR, Merrill AH, Jr., Bell RM. Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets. J Biol Chem 1986; 261: 12604-12609.
6. Wilson E, Wang E, Mullins RE, Liotta DC, Lambeth JD, Merrill AH, Jr. Modulation of the free sphingosine levels in human neutrophils by phorbol esters and other factors. J Biol Chem 1988; 263: 9304-9309.
7. Spiegel S, Olivera A, Carlson RO. The role of sphingosine in cell growth regulation and transmembrane signaling. Adv Lipid Res 1993; 25: 105-129.
8. Spiegel S, Cuvillier O, Edsall LC, et al. Sphingosine-1-phosphate in cell growth and cell death. Ann NY Acad Sci 1998; 845: 11-18.
9. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4: 397-407.
10. Pettus BJ, Bielawska A, Subramanian P, et al. Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem 2004; 279: 11320-11326.
11. Urtz N, Olivera A, Bofill-Cardona E, et al. Early activation of sphingosine kinase in mast cells and recruitment to FcepsilonRI are mediated by its interaction with Lyn kinase. Mol Cell Biol 2004; 24: 8765-8777.
12. Hla T. Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol 2004; 15: 513-520.
13. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling and termination at lipid phosphate receptors. Biochim Biophys Acta 2002; 1582: 121-131.
14. Saba JD, Hla T. Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res 2004; 94: 724-734.
15. Baumruker T, Bornancin F, Billich A. The role of sphingosine and ceramide kinases in inflammatory responses. Immunol Lett 2005; 96: 175-185.
16. Anliker B, Chun J. Cell surface receptors in lysophospholipid signaling. Semin Cell Dev Biol 2004; 15: 457-465.
17. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 2004; 92: 949-966.
18. Kostenis E. Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: new receptors for "old" ligands. J Cell Biochem 2004; 92: 923-936.
19. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004; 92: 913-922.
20. Goetzl EJ, Wang W, McGiffert C, Huang MC, Graler MH. Sphingosine 1-phosphate and its G protein-coupled receptors constitute a multifunctional immunoregulatory system. J Cell Biochem 2004; 92: 1104-1114.
21. Yatomi Y, Igarashi Y, Yang L, et al. Sphingosine-1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem Tokyo 1997; 121: 969-973.
22. Liu H, Chakravarty D, Maceyka M, Milstien S, Spiegel S. Sphingosine kinases: a novel family of lipid kinases. Prog Nucleic Acid Res Mol Biol 2002; 71: 493-511.
23. Billich A, Bornancin F, Mechtcheriakova D, Natt F, Huesken D, Baumruker T. IL-1 and TNF-induced production of inflammatory mediators in A549 epithelial lung carcinoma cells is dependent on sphingosine kinase 1 activity. Cell Signal 2005; 17: 1203-1217.
24. Sugiura M, Kono K, Liu H, Shimizugawa T, Minekura H, Spiegel S, Kohama T. Ceramide kinase, a novel lipid kinase. Molecular cloning and functional characterization. J Biol Chem 2002; 277: 23294-23300.
25. Waggoner DW, Johnson LB, Mann PC, Morris V, Guastella J, Bajjalieh SM. MuLK, a eukaryotic multi-substrate lipid kinase. J Biol Chem 2004; 279: 38228-38235.
26. Fukuda Y, Kihara A, Igarashi Y. Distribution of sphingosine kinase activity in mouse tissues: contribution of SPHK1. Biochem Biophys Res Commun 2003; 309: 155-160.
27. Yatomi Y, Ohmori T, Rile G, et al. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 2000; 96: 3431-3438.
28. English D, Welch Z, Kovala AT, et al. Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis. FASEB J 2000; 14: 2255-2265.
29. Banno Y, Kato M, Hara A, Nozawa Y. Evidence for the presence of multiple forms of Sph kinase in human platelets. Biochem J 1998; 335: 301-304.
30. Allende ML, Sasaki T, Kawai H, et al. Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 2004; 279: 52487-52492.
31. 2+ signalling by G-protein-coupled receptors. EMBO J 1998; 17: 2830-2837.
32. Blaukat A, Dikic I. Activation of sphingosine kinase by the bradykinin B2 receptor and its implication in regulation of the ERK/MAP kinase pathway. Biol Chem 2001; 382: 135-139.
33. Alemany R, Meyer zu Heringdorf, van Koppen CJ, Jakobs KH. Formyl peptide receptor signaling in HL-60 cells through sphingosine kinase. J Biol Chem 1999; 274: 3994-3999.
34. Meyer zu Heringdorf, Lass H, Kuchar I, et al. Stimulation of intracellular sphingosine-1-phosphate production by G-protein-coupled sphingosine-1-phosphate receptors. Eur J Pharmacol 2001; 414: 145-154.
35. Edsall LC, Pirianov GG, Spiegel S. Involvement of sphingosine 1-phosphate 1n nerve growth factor-mediated neuronal survival and differentiation. J Neurosci 1997; 17: 6952-6960.
36. Olivera A, Spiegel S. Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens. Nature 1993; 365: 557-560.
37. Wu W, Mosteller RD, Broek D. Sphingosine kinase protects lipopolysaccharide-activated macrophages from apoptosis. Mol Cell Biol 2004; 24: 7359-7369.
38. Choi OH, Kim JH, Kinet JP. Calcium mobilization via sphingosine kinase in signalling by the Fc epsilon RI antigen receptor. Nature 1996; 380: 634-636.
39. Melendez A, Floto RA, Gillooly DJ, Harnett MM, Allen JM. Fc gamma RI coupling to phospholipase D initiates sphingosine kinase-mediated calcium mobilization and vesicular trafficking. J Biol Chem 1998; 273: 9393-9402.
40. Xia P, Gamble JR, Rye KA, et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA 1998; 95: 14196-14201.
41. Pettus BJ, Bielawski J, Porcelli AM, et al. The sphingosine kinase 1/ sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J 2003; 17: 1411-1421.
42. Jolly PS, Bektas M, Olivera A, et al. Transactivation of Sphingosine-1-Phosphate Receptors by FcεRI Triggering Is Required for Normal Mast Cell Degranulation and Chemotaxis. J Exp Med 2004; 199: 959-970.
43. Shu X, Wu W, Mosteller RD, Broek D. Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol Cell Biol 2002; 22: 7758-7768.
44. Chen XL, Grey JY, Thomas S, et al. Sphingosine kinase-1 mediates TNF-alpha-induced MCP-1 gene expression in endothelial cells: upregulation by oscillatory flow. Am J Physiol Heart Circ Physiol 2004; 287: 1452-1458.
45. Ibrahim FB, Pang SJ, Melendez AJ. Anaphylatoxin signaling in human neutrophils. A key role for sphingosine kinase. J Biol Chem 2004; 279: 44802-44811.
46. 2+ signals, enzyme release, cytokine production, and chemotaxis. J Immunol 2004; 173: 1596-1603.
47. Yamanaka M, Shegogue D, Pei H, et al. Sphingosine kinase 1 (SPHK1) is induced by transforming growth factor-beta and mediates TIMP-1 up-regulation. J Biol Chem 2004; 279: 53994-54001.
48. Pitson SM, Moretti PA, Zebol JR, et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J. 2003; 22: 5491-5500.
49. Johnson KR, Becker KP, Facchinetti MM, Hannun YA, Obeid LM. PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). J Biol Chem 2002; 277: 35257-35262.
50. Pitson SM, Moretti PA, Zebol JR, et al. Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase. J Biol Chem 2000; 275: 33945-33950.
51. Blom T, Slotte JP, Pitson SM, Tornquist K. Enhancement of intracelluIar sphingosine-1-phosphate production by inositol 1,4,5-trisphosphate-evoked calcium mobilisation in HEK-293 cells: endogenous sphingosine-1-phosphate as a modulator of the calcium response. Cell Signal 2005; 17: 827-836.
52. Melendez AJ, Khaw AK. Dichotomy of Ca2+ signals triggered by different phospholipid pathways in antigen stimulation of human mast cells. J Biol Chem 2002; 277: 17255-17262.
53. Rosenfeldt HM, Hobson JP, Maceyka M, et al. EDG-1 links the PDGF receptor to Src and focal adhesion kinase activation leading to lamellipodia formation and cell migration. FASEB J 2001; 15: 2649-2659.
54. 2+/calmodulin- dependent translocation of sphingosine kinase: role in plasma membrane relocation but not activation. Cell Calcium 2003; 33: 119-128.
55. Toman RE, Payne SG, Watterson KR, et al. Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol 2004; 166: 381-392.
56. Olivera A, Rosenthal J, Spiegel S. Effects of acidic phospholipids on sphingosine kinase. J Cell Biochem 1996; 60: 529-537.
57. Pitson SM, Xia P, Leclercq TM, et al. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med 2005; 201: 49-54.
58. Safadi-Chamberlain F, Wang LP, Payne SG, et al. Effect of a membrane-targeted sphingosine kinase 1 on cell proliferation and survival. Biochem J 2005; 388: 827-34.
59. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura SI. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J Biol Chem 2003; 278: 46832-46839.
60. Liu H, Toman RE, Goparaju SK, et al. Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem 2003; 278: 40330-40336.
61. Delon C, Manifava M, Wood E, et al. Sphingosine kinase 1 is an intracellular effector of phosphatidic acid. J Biol Chem 2004; 279: 44763-44774.
62. 2+/ calmodulin-dependent translocation of sphingosine kinase; role in plasma membrane relocation but not activation. Cell Calcium 2003; 33: 119-128
63. Thompson CR, Iyer SS, Melrose N, et al. Sphingosine kinase 1 (SK1) is recruited to nascent phagosomes in human macrophages: inhibition of SK1 translocation by Mycobacterium tuberculosis. J Immunol 2005; 174: 3551-3561.
64. Rius RA, Edsall LC, Spiegel S. Activation of sphingosine kinase in pheochromocytoma PC12 neuronal cells in response to trophic factors. FEBS Lett 1997; 417: 173-176.
65. Buehrer BM, Bardes ES, Bell RM. Protein kinase C-dependent regulation of human erythroleukemia (HEL) cell sphingosine kinase activity. Biochim Biophys Acta 1996; 1303: 233-242.
66. Kleuser B, Cuvillier O, Spiegel S. 1alpha25-dihydroxyvitamin D3 inhibits programmed cell death in HL-60 cells by activation of sphingosine kinase. Cancer Res 1998; 58: 1817-1824.
67. Auge N, Nikolova-Karakashian M, Carpentier S, et al. Role of sphingosine 1-phosphate in the mitogenesis induced by oxidized low density lipoprotein in smooth muscle cells via activation of sphingomyelinase, ceramidase, and sphingosine kinase. J Biol Chem 1999; 274: 21533-21538.
68. Nakade Y, Banno Y, Koizumi K, et al. Regulation of sphingosine kinase 1 gene expression by protein kinase C in a human leukemia cell line, MEG-O1. Biochim Biophys Acta 2003; 1635: 104-116.
69. Argraves KM, Wilkerson BA, Argraves WS, Fleming PA, Obeid LM, Drake CJ. Sphingosine-1-phosphate signaling promotes critical migratory events in vasculogenesis. J Biol Chem 2004; 279: 50580-50590.
70. Taha TA, Kitatani K, Bielawski J, Cho W, Hannan YA, Obeid LM. TNF induces the loss of sphingosine kinase-1 by a cathepsin B dependent mechanism. J Biol Chem 2005. In press.
71. Sano T, Baker D, Virag T, et al. Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem 2002; 277: 21197-21206.
72. Yang L, Yatomi Y, Miura Y, Satoh K, Ozaki Y. Metabolism and functional effects of sphingolipids in blood cells. Br J Haematol 1999; 107: 282-293.
73. Yamamura S, Yatomi Y, Ruan F, Sweetney EA, Hakomori S, Igarashi Y. Sphingosine-1-phosphate regulates melanoma cell motility through a receptor-coupled extracellular action and in a pertussis toxin-insensitive manner. Biochemistry 1997; 36: 10751-10759.
74. Vann LR, Payne SG, Edsall LC, Twitty S, Spiegel S, Milstien S. Involvement of sphingosine kinase in TNF-alpha-stimulated tetrahydrobiopterin biosynthesis in C6 glioma cells. J Biol Chem 2002; 277: 12649-12656.
75. Anelli V, Bassi R, Tettamanti G, Viani P, Riboni L. Extracellular release of newly synthesized sphingosine-1-phosphate by cerebellar granule cells and astrocytes. J Neurochem 2005; 92: 1204-1215.
76. Prieschl EE, Csonga R, Novotny V, Kikuchi GE, Baumruker T. The balance between sphingosine and sphingosine-1-phosphate is decisive for mast cell activation after Fc epsilon receptor 1 triggering. J Exp Med 1999; 190: 1-8.
77. Ancellin N, Colmont C, Su J, et al. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem 2002; 277: 6667-6675.
78. Waters C, Sambi B, Kong KC, et al. Sphingosine 1-phosphate and platelet-derived growth factor (PDGF) act via PDGF beta receptor-sphingosine 1-phosphate receptor complexes in airway smooth muscle cells. J Biol Chem 2003; 278: 6282-6290.
79. Jolly PS, Bektas M, Watterson KR, et al. Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by desensitizing S1P receptors. Blood 2005; 105: 4736-4742
80. Meacci E, Cencetti F, Donati C, Nuti F, Becciolini L, Bruni P. Sphingosine kinase activity is required for sphingosine-mediated phospholipase D activation in C2C12 myoblasts. Biochem J 2004; 381: 655-663.
81. Allende ML, Proia RL. Sphingosine-1-phosphate receptors and the development of the vascular system. Biochim Biophys Acta 2002; 1582: 222-227.
82. McVerry BJ, Garcia JG. Endothelial cell barrier regulation by sphingosine 1-phosphate. J Cell Biochem 2004; 92: 1075-1085.
83. Kluk MJ, Hla T. Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ Res 2001; 89: 496-502.
84. Geoffroy K, Troncy L, Wiernsperger N, Lagarde M, El Bawab S. Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett 2005; 579: 1249-1254.
85. Jolly PS, Rosenfeldt HM, Milstien S, Spiegel S. The roles of sphingosine-1-phosphate in asthma. Mol Immunol 2002; 38: 1239-1245.
86. Deutschman DH, Carstens JS, Klepper RL, et al. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J 2003; 146: 62-68.
87. Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002; 14: 569-575.
88. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004; 4: 1019-1025.
89. Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett 2003; 554: 189-193.
90. Sanchez T, Estrada-Hernandez T, Paik JH, et al. Phosphorylation and Action of the Immunomodulator FTY720 Inhibits Vascular Endothelial Cell Growth Factor-induced Vascular Permeability. J Biol Chem 2003; 278: 47281-47290.
91. Billich A, Bornancin F, Devay P, Mechtcheriakova D, Urtz N, Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem 2003; 278: 47408-47415.
92. Billich A. Phosphorylation of FTY720 by sphingosine kinases. In: Böhler T Ed., FTY720 - Mode of action. Bremen, Uni-Med Science, In press.
93. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-21457.
94. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-349.
95. Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J Biol Chem 2004; 279: 15396-15401.
96. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355-360.
97. Chiba K, Yanagawa Y, Masubuchi Y, et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J Immunol. 1998; 160: 5037-5044.
98. Yagi H, Kamba R, Chiba K, et al. Immunosuppressant FTY720 inhibits thymocyte emigration. Eur J Immunol 2000; 30: 1435-1444.
99. Rosen H, Alfonso C, Surh CD, McHeyzer-Williams MG. Rapid induction of medullary thymocyte phenotypic maturation and egress inhibition by nanomolar sphingosine 1-phosphate receptor agonist. Proc Natl Acad Sci USA 2003; 100: 10907-10912.
100. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004; 18: 551-553.
101. 2+ mobilization independently of G-protein-coupled receptors. FEBS Lett 2003; 554: 443-449.
102. Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim Biophys Acta 2002; 1585: 193-201.
103. Cuvillier O, Andrieu-Abadie N, Segui B, et al. Sphingolipid-mediated apoptotic signaling pathways. J.Soc.Biol. 2003; 197: 217-221.
104. Olivera A, Kohama T, Edsall L, et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 1999; 147: 545-558.
105. Xia P, Wang L, Moretti PA, et al. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. J Biol Chem 2002; 277: 7996-8003.
106. French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003; 63: 5962-5969.
107. Rundall BK, Denlinger CE, Jones DR. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 2004; 136: 416-425.
108. Taha, TA, Osta W, Kozhaya L, et al. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J Biol Chem 2004; 279: 20546-20554.
109. Mitsutake S, Kim TJ, Inagaki Y, Kato M, Yamashita T, Igarashi Y. Ceramide kinase is a mediator of calcium-dependent degranulation in mast cells. J Biol Chem 2004; 279: 17570-17577.
110. Min J, Traynor D, Stegner AL, et al. Sphingosine kinase regulates the sensitivity of Dictyostelium discoideum cells to the anticancer drug cisplatin. Eukaryot Cell 2005; 4: 178-189.
111. Min J, Stegner AL, Alexander H, Alexander S. Overexpression of sphingosine-1-phosphate lyase or inhibition of sphingosine kinase in Dictyostelium discoideum results in a selective increase in sensitivity to platinum-based chemotherapy drugs. Eukaryot Cell 2004; 3: 795-805.
112. Sukocheva OA, Wang L, Albanese N, Pitson SM, Vadas MA, Xia P. Sphingosine kinase transmits estrogen signaling in human breast cancer cells. Mol Endocrinol 2003; 17: 2002-2012.
113. Fukuda Y, Aoyama Y, Wada A, Igarashi Y. Identification of PECAM-1 association with sphingosine kinase 1 and its regulation by agonist-induced phosphorylation. Biochim Biophys Acta 2004; 1636: 12-21.
114. MacKinnon AC, Buckley A, Chilvers ER, Rossi AG, Haslett C, Sethi T. Sphingosine kinase: a point of convergence in the action of diverse neutrophil priming agents. J Immunol 2002; 169: 6394-6400.
115. Lee C, Xu DZ, Feketeova E, et al. Attenuation of shock-induced acute lung injury by sphingosine kinase inhibition. J Trauma 2004; 57: 955-960.
116. Kee TH, Vit P, Melendez AJ. Sphingosine kinase signalling in immune cells. Clin Exp Pharmacol Physiol 2005; 32: 153-161.
117. Bornancin F, Mechtcheriakova D, Stora S, et al. Characterization of a ceramide kinase-like protein. Biochim Biophys Acta 2005; 1687: 31-43.
118. Tuson M, Marfany G, Gonzalez-Duarte R. Mutation of CERKL, a novel human ceramide kinase gene, causes autosomal recessive retinitis pigmentosa (RP26). Am J Hum Genet 2004; 74: 128-138.
119. Bajjalieh SM, Martin TF, Floor E. Synaptic vesicle ceramide kinase. A calcium-stimulated lipid kinase that co-purifies with brain synaptic vesicles. J Biol Chem 1989; 264: 14354-14360.
120. Carre A, Graf C, Stora S, et al. Ceramide kinase targeting and activity determined by its N-terminal pleckstrin homology domain. Biochem Biophys Res Commun 2004; 324: 1215-1219.
121. Pettus BJ, Bielawska. A, Spiegel S, Roddy P, Hannun YA, Chalfant CE. Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release. J Biol Chem 2003; 278: 38206-38213.
122. Pettus BJ, Chalfant CE, Hannun YA. Sphingolipids in inflammation: roles and implications. Curr Mol Med 2004; 4: 405-418.
123. Subramanian P, Stahelin RV, Szulc Z, Bielawska A, Cho W, Chalfant CE. Ceramide-1-phosphate acts as a positive allosteric activator of group IVA cytosolic phospholipase A2 alpha and enhances the interaction of the enzyme with phosphatidylcholine. J Biol Chem 2005; 280(18): 17601-7.
124. Gomez-Munoz A. Ceramide-1-phosphate: a novel regulator of cell activation. FEBS Lett 2004; 562: 5-10.
125. Gomez-Munoz A, Frago LM, Alvarez L, Varela-Nieto I. Stimulation of DNA synthesis by natural ceramide 1-phosphate. Biochem J 1997; 325: 435-440.
126. Gomez-Munoz A, Kong JY, Salh B, Steinbrecher UP. Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophages. J Lipid Res 2004; 45: 99-105.
127. Liang H, Yao N, Song JT, Luo S, Lu H, Greenberg JT. Ceramides modulate programmed cell death in plants. Genes Dev 2003; 17: 2636-2641.
128. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 1972; 175: 720-731.
129. Edidin M. Lipids on the frontier: a century of cell-membrane bilayers. Nat Rev Mol Cell Biol 2003; 4: 414-418.
130. Lai EC. Lipid rafts make for slippery platforms. J Cell Biol 2003; 162: 365-370.
131. Binder WH, Barragan V, Menger FM. Domains and rafts in lipid membranes. Angew Chem Int Ed Engl 2003; 42: 5802-5827.
132. Houslay MD, Stanley KK. Dynamics of biological membranes. Wiley, New York. 1982: 1-92.
133. Wu WG, Chi LM. Conformational change of cholesterol side chain in lipid bilayers. J.Am Chem Soc 2005; 113: 4683-4685.
134. Cremesti AE, Goni FM, Kolesnick R. Role of sphingomyelinase and ceramide in modulating rafts: do biophysical properties determine biologic outcome? FEBS Lett 2002; 531: 47-53.
135. Kolesnick R. The therapeutic potential of modulating the ceramide/ sphingomyelin pathway. J Clin Invest 2002; 110: 3-8.
136. Kolesnick RN, Goni FM, Alonso A. Compartmentalization of ceramide signaling: physical foundations and biological effects. J Cell Physiol 2000; 184: 285-300.
137. Veiga MP, Arrondo JL, Goni FM, Alonso A. Ceramides in phospholipid membranes: effects on bilayer stability and transition to nonlamellar phases. Biophys J 1999; 76: 342-350.
138. Mayor S, Rao M. Rafts: scale-dependent, active lipid organization at the cell surface. Traffic 2004; 5: 231-240.
139. Kusumi A, Sako Y. Cell surface organization by the membrane skeleton. Curr Opin Cell Biol 1996; 8: 566-574.
140. Sako Y, Nagafuchi A, Tsukita S, Takeichi M, Kusumi A. Cytoplasmic regulation of the movement of E-cadherin on the free cell surface as studied by optical tweezers and single particle tracking: corralling and tethering by the membrane skeleton. J Cell Biol 1998; 140: 1227-1240.
141. Fujiwara T, Ritchie K, Murakoshi H, Jacobson K, Kusumi A. Phospholipids undergo hop diffusion in compartmentalized cell membrane. J Cell Biol 2002; 157: 1071-1081.
142. Kusumi A, Koyama-Honda I, Suzuki K. Molecular dynamics and interactions for creation of stimulation-induced stabilized rafts from small unstable steady-state rafts. Traffic 2004; 5: 213-230.
143. Dietrich C, Yang B, Fujiwara T, Kusumi A, Jacobson K. Relationship of lipid rafts to transient confinement zones detected by single particle tracking. Biophys J 2002; 82: 274-284.
144. Simson R, Sheets ED, Jacobson K. Detection of temporary lateral confinement of membrane proteins using single-particle tracking analysis. Biophys J 1995; 69: 989-993.
145. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569-572.
146. Anderson RG, Jacobson K. A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 2002; 296: 1821-1825.
147. Thompson TE, Tillack TW. Organization of glycosphingolipids in bilayers and plasma membranes of mammalian cells. Annu Rev Biophys Biophys Chem 1985; 14: 361-386.
148. Radhakrishnan A, Anderson TG, McConnell HM. Condensed complexes, rafts, and the chemical activity of cholesterol in membranes. Proc Natl Acad Sci USA 2000; 97: 12422-12427.
149. Garmy N, Taieb N, Yahi N, Fantini J. Interaction of cholesterol with sphingosine: physicochemical characterization and impact on intestinal absorption. J Lipid Res 2005; 46: 36-45.
150. Resh MD. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim Biophys Acta 1999; 1451: 1-16.
151. Liu P, Wang P, Michaely P, Zhu M, Anderson RG. Presence of oxidized cholesterol in caveolae uncouples active platelet-derived growth factor receptors from tyrosine kinase substrates. J Biol Chem 2000; 275: 31648-31654.
152. Okamoto Y, Ninomiya H, Miwa S, Masaki T. Cholesterol oxidation switches the internalization pathway of endothelin receptor type A from caveolae to clathrin-coated pits in Chinese hamster ovary cells. J Biol Chem 2000; 275: 6439-6446.
153. Mahfoud R, Garmy N, Maresca M, Yahi N, Puigserver A, Fantini J. Identification of a common sphingolipid-binding domain in Alzheimer, prion, and HIV-1 proteins. J Biol Chem 2002; 277: 11292-11296.
154. Kinet JP, Quarto R, Perez-Montfort R, Metzger H. Noncovalently and covalently bound lipid on the receptor for immunoglobulin E. Biochemistry 1985; 24: 7342-7348.
155. Hedo JA, Collier E, Watkinson A. Myristyl and palmityl acylation of the insulin receptor. J Biol Chem 1987; 262: 954-957.
156. Bourguignon LY, Bourguignon GJ. Capping and the cytoskeleton. Int Rev Cytol 1984; 87: 195-224.
157. Cremesti A, Paris F, Grassme H, et al. Ceramide enables fas to cap and kill. J Biol Chem 2001; 276: 23954-23961.
158. Harder T, Simons K. Clusters of glycolipid and glycosylphosphatidylinositol-anchored proteins in lymphoid cells: accumulation of actin regulated by local tyrosine phosphorylation. Eur J Immunol 1999; 29: 556-562.
159. Smart EJ, Graf GA, McNiven MA, et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 1999; 19: 7289-7304.
160. Chatterjee S. Neutral sphingomyelinase action stimulates signal transduction of tumor necrosis factor-alpha in the synthesis of cholesteryl esters in human fibroblasts. J Biol Chem 1994; 269: 879-882.
161. Maxfield FR. Plasma membrane microdomains. Curr Opin Cell Biol 2002; 14: 483-487.
162. Heerklotz H. Triton promotes domain formation in lipid raft mixtures. Biophys J 2002; 83: 2693-2701.
163. Schuck S, Honsho M, Ekroos K, Shevchenko A, Simons K. Resistance of cell membranes to different detergents. Proc Natl Acad Sci USA 2003; 100: 5795-5800.
164. Sheets ED, Lee GM, Simson R, Jacobson K. Transient confinement of a glycosylphosphatidylinositol-anchored protein in the plasma membrane. Biochemistry 1997; 36: 12449-12458.
165. Dykstra M, Cherukuri A, Sohn HW, Tzeng SJ, Pierce SK. Location is everything: lipid rafts and immune cell signaling. Annu Rev Immunol 2003; 21: 457-481.
166. Harder T. Raft membrane domains and immunoreceptor functions. Adv Immunol 2001; 77: 45-92.
167. Field KA, Holowka D, Baird B. Compartmentalized activation of the high affinity inummoglobulin E receptor with membrane domains. J Biol Chem 1997; 272: 4276-4280.
168. Cheng PC, Dykstra ML, Mitchell RN, Pierce SK. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med 1999; 190: 1549-1560.
169. Giurisato E, McIntosh DP, Tassi M, Gamberucci A, Benedetti A. T cell receptor can be recruited to a subset of plasma membrane rafts, independently of cell signaling and attendantly to raft clustering. J Biol Chem 2003; 278: 6771-6778.
170. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002; 107: 176-182.
171. Burack WR, Lee KH, Holdorf AD, Dustin ML, Shaw AS. Cutting edge: quantitative imaging of raft accumulation in the immunological synapse. J Immumol 2002; 169: 2837-2841.
172. Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999; 283: 680-682.
173. Cherukuri A, Cheng PC, Sohn HW, Pierce SK. The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity 2001; 14: 169-179.
174. Ehrlich LI, Ebert PJ, Krummel MF, Weiss A, Davis MM. Dynamics of p561ck translocation to the T cell immunological synapse following agonist and antagonist stimulation. Immunity 2002; 17: 809-822.
175. Tuosto L, Parolini I, Schroder S, Sargiacomo M, Lanzavecchia A, Viola A. Organization of plasma membrane functional rafts upon T cell activation. Eur J Immunol 2001; 31: 345-349.
176. Cheong KH, Zacchetti D, Schneeberger EE, Simons K. VIP17/MAL, a lipid raft-associated protein, is involved in apical transport in MDCK cells. Proc Natl Acad Sci USA 1999; 96: 6241-6248.
177. Millan J, Alonso MA. MAL, a novel integral membrane protein of human T lymphocytes, associates with glycosylphosphatidylinositol-anchored proteins and Src-like tyrosine kinases. Eur J Immunol 1998; 28: 3675-3684.
178. Lafont F, Simons K. Raft-partitioning of the ubiquitin ligases Cbl and Nedd4 upon IgE-triggered cell signaling. Proc Natl Acad Sci USA 2001; 98: 3180-3184.
179. Guo B, Kato RM, Garcia-Lloret M, Wahl MI, Rawlings DJ. Engagement of the human pre-B cell receptor generates a lipid raft-dependent calcium signaling complex. Immunity 2000; 13: 243-253.
180. Saint-Ruf C, Panigada M, Azogui O, Debey P, von Boehmer H, Grassi F. Different initiation of pre-TCR and gammadeltaTCR signalling. Nature 2000; 406: 524-527.
181. Sproul TW, Malapati S, Kim J, Pierce SK. Cutting edge: B cell antigen receptor signaling occurs outside lipid rafts in immature B cells. J Immunol 2000; 165: 6020-6023.
182. Ebert PJ, Baker JF, Punt JA. Immature CD4+ CD8+ thymocytes do not polarize lipid rafts in response to TCR-mediated signals. J Immunol 2000; 165: 5435-5442.
183. Marmor MD, Julius M. Role for lipid rafts in regulating interleukin-2 receptor signaling. Blood 2001; 98: 1489-1497.
184. Prior IA, Muncke C, Parton RG, Hancock JF. Direct visualization of Ras proteins in spatially distinct cell surface microdomains. J Cell Biol 2003; 160: 165-170.
185. Barenholz Y. Sphingomyelin and cholesterol: from membrane biophysics and rafts to potential medical applications. Subcell Biochem 2004; 37: 167-215.
186. Pralle A, Keller P, Florin EL, Simons K, Horber JK. Sphingolipid-cholesterol rafts diffuse as small entities in the plasma membrane of mammalian cells. J Cell Biol 2000; 148: 997-1008.
187. Freiberg BA, Kupfer H, Maslanik W, et al. Staging and resetting T cell activation in SMACs. Nat Immunol 2002; 3: 911-917.
188. Ike H, Kosugi A, Kato A, et al. Mechanism of Lck recruitment to the T-cell receptor cluster as studied by single-molecule-fluorescence video imaging. Chemphyschem 2003; 4: 620-626.
189. Lindquist JA, Simeoni L, Schraven B. Transmembrane adapters: attractants for cytoplasmic effectors. Immunol. Rev 2003; 191: 165-182.
190. Justement LB. The role of CD45 in signal transduction. Adv Immunol 1997; 66:1-65.
191. Irles C, Symons A, Michel F, Bakker TR, van der Merwe PA, Acuto O. CD45 ectodomain controls interaction with GEMs and Lck activity for optimal TCR signaling. Nat Immunol 2003; 4: 189-197.
192. Harder T, Engelhardt KR. Membrane domains in lymphocytes - from lipid rafts to protein scaffolds. Traffic 2004; 5: 265-275.
193. Abdel Shakor AB, Kwiatkowska K, Sobota A. Cell surface ceramide generation precedes and controls FcgammaRII clustering and phosphorylation in rafts. J Biol Chem 2004; 279: 36778-36787.
194. Stuermer CA, Lang DM, Kirsch F, Wiechers M, Deininger SO, Plattner H. Glycosylphosphatidyl inositol-anchored proteins and fyn kinase assemble in noncaveolar plasma membrane microdomains defined by reggie-1 and -2. Mol Biol Cell 2001; 12: 3031-3045.
195. Slaughter N, Laux I, Tu X, et al. The flotillins are integral membrane proteins in lipid rafts that contain TCR-associated signaling components: implications for T-cell activation. Clin Immunol 2003; 108: 138-151.
196. Rajendran L, Masilamani M, Solomon S, et al. Asymmetric localization of flotillins/reggies in preassembled platforms confers inherent polarity to hematopoietic cells. Proc Natl Acad Sci USA 2003; 100: 8241-8246.
197. Saeki K, Miura Y, Aki D, Kurosaki T, Yoshimura A. The B cell-specific major raft protein, Raftlin, is necessary for the integrity of lipid raft and BCR signal transduction. EMBO J 2003; 22: 3015-3026.
198. Kimura A, Baumann CA, Chiang SH, Saltiel AR. The sorbin homology domain: a motif for the targeting of proteins to lipid rafts. Proc Natl Acad Sci USA 2001; 98: 9098-9103.
199. Volonte D, Galbiati F, Li S, Nishiyama K, Okamoto T, Lisanti MP. Flotillins/cavatellins are differentially expressed in cells and tissues and form a hetero-oligomeric complex with caveolins in vivo. Characterization and epitope-mapping of a novel flotillin-1 monoclonal antibody probe. J Biol Chem 1999; 274: 12702-12709.
200. van der Merwe PA. Formation and function of the immunological synapse. Curr Opin Immunol 2002; 14: 293-298.
201. Davis DM. Assembly of the immunological synapse for T cells and NK cells. Trends Immunol 2002; 23: 356-363.
202. Batista FD, Iber D, Neuberger MS. B cells acquire antigen from target cells after synapse formation. Nature 2001; 411: 489-494.
203. Dupre L, Aiuti A, Trifari S, et al. Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. Immunity 2002; 17: 157-166.
204. Villalba M, Bi K, Rodriguez F, Tanaka Y, Schoenberger S, Altman A. Vav1/ Rac-dependent actin cytoskeleton reorganization is required for lipid raft clustering in T cells. J Cell Biol 2001; 155: 331-338.
205. Lin J, Weiss A. The tyrosine phosphatase CD148 is excluded from the immunologic synapse and down-regulates prolonged T cell signaling. J Cell Biol 2003; 162: 673-682.
206. Hannun YA, Bell RM. Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. Science 1987; 235: 670-674.
207. Kashiwagi K, Shirai Y, Kuriyama M, Sakai N, Saito N. Importance of C1B domain for lipid messenger-induced targeting of protein kinase C. J Biol Chem 2002; 277: 18037-18045.
208. Megidish T, White T, Takio K, Titani K, Igarashi Y, Hakomori S. The signal modulator protein 14-3-3 is a target of sphingosine- or N,N-dimethylsphingosine-dependent kinase in 3T3(A31) cells. Biochem Biophys Res Common 1995; 216: 739-747.
209. McDonald OB, Hannon YA, Reynolds CH, Sahyoun N. Activation of casein kinase II by sphingosine. J Biol Chem 1991; 266: 21773-21776.
210. King CC, Zenke FT, Dawson PE, et al. Sphingosine is a novel activator of 3-phosphoinositide-dependent kinase 1. J Biol Chem 2000; 275: 18108-18113.
211. Faucher M, Girones N, Hannun YA, Bell RM, Davis RJ. Regulation of the epidermal growth factor receptor phosphorylation state by sphingosine in A431 human epidermoid carcinoma cells. J Biol Chem 1988; 263: 5319-5327.
212. Davis RJ, Girones N, Faucher M. Two alternative mechanisms control the interconversion of functional states of the epidermal growth factor receptor. J Biol Chem 1988; 263: 5373-5379.
213. Boucher LM, Wiegmann K, Futterer A, et al. CD28 signals through acidic sphingomyelinase [see comments]. J Exp Med 1995; 181: 2059-2068.
214. Koppenhoefer U, Brenner B, Lang F, Gulbins E. The CD40-ligand stimulates T-lymphocytes via the neutral sphingomyelinase: a novel function of the CD40-ligand as signalling molecule. FEBS Lett 1997; 414: 444-448.